Federated Hermes, Inc. Adverum Biotechnologies, Inc. Transaction History

Federated Hermes, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $4,249 - $7,029	-5,246 Reduced 51.7%	4,901 $6,000
Q1 2022 May 13, 2022	BUY	$1.23 - $1.95 $5,685 - $9,012	4,622 Added 83.66%	10,147 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $1,604 - $2,212	922 Added 20.03%	5,525 $10,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $8,654 - $14,979	4,161 Added 941.4%	4,603 $10,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $1,485 - $4,667	442 New	442 $2,000
Q4 2020 Feb 12, 2021	SELL	$9.84 - $14.26 $822,791 - $1.19 Million	-83,617 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$10.3 - $21.64 $1.48 Million - $3.12 Million	-144,074 Reduced 63.28%	83,617 $861,000
Q2 2020 Aug 13, 2020	BUY	$8.53 - $25.64 $1.94 Million - $5.84 Million	227,691 New	227,691 $4.75 Million
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $2,462 - $7,468	-470 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $2,397 - $5,588	470 New	470 $6,000
Q3 2018 Nov 13, 2018	SELL	$4.5 - $7.6 $5,175 - $8,740	-1,150 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$3.65 - $7.95 $4,588 - $9,993	-1,257 Reduced 52.22%	1,150 $7,000
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $3,180 - $4,408	1,116 Added 86.44%	2,407 $0
Q3 2017 Nov 13, 2017	BUY	$2.45 - $3.65 $3,162 - $4,712	1,291	1,291 $5,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.